Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Earnings data Q3 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles (December 4-7, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).

Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

NEW YORK, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral presentations at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) in Washington, D.C. (Embassy of France, December 5-7, 2019) outlining the design and rational for the ARISE-HF study. ARISE-HF is a Phase 3 pivotal study examining effects of AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), on functional capacity (as measured by peak V02) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression.

Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT)

NEW YORK, Nov.  12, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a definitive securities purchase agreement, dated as of November 7, 2019, for the sale of its common stock, par value $0.0001 per share (the “Shares”), in a private placement (the “Private Placement”) expected to result in gross proceeds to the Company of approximately $20 million, before deducting placement agent commissions and other offering expenses.

Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock

Avantor Inc.

Fastly

 Luckin Coffee

Postal Realty Trust

U.S. IPO Week Ahead: Just One Biotech Is On The Calendar In A Slow Week For The IPO Market

NEW YORK, Sept.  17, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona (September 16-20, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).

Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

NEW YORK, Sept.  13, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting in Philadelphia (September 13-16, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM). The presentation, titled “Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy,” further supports the development rationale and clinical proof of concept for AT-001 in DbCM. 

Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting

News for Applied Therapeutics Inc Stock (APLT)